We are live on ! Find out more
AMED

Amedisys
AMED

Delisted

AMED was delisted on the 14th of August, 2025.

Back to rankings

288 hedge funds and large institutions have $2.85B invested in Amedisys in 2024 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 93 increasing their positions, 104 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 32

18% more funds holding in top 10

Funds holding in top 10: 11 → 13 (+2)

2% more funds holding

Funds holding: 283 → 288 (+5)

0.07% more ownership

Funds ownership: 94.92% → 94.99% (+0.07%)

0% less capital invested

Capital invested by funds: $2.86B → $2.85B (-$5.8M)

11% less repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 104

82% less call options, than puts

Call options by funds: $17.1M | Put options by funds: $94.3M

Holders
288
Holders Change
+5
Holders Change %
+1.77%
% of All Funds
4.16%
Holding in Top 10
13
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+18.18%
% of All Funds
0.19%
New
42
Increased
93
Reduced
104
Closed
32
Calls
$17.1M
Puts
$94.3M
Net Calls
-$77.2M
Net Calls Change
-$8.21M

Top Buyers

1
Goldman Sachs
Goldman Sachs
New York
+$96.9M
2
FCM
Farallon Capital Management
California
+$27.9M
3
AllianceBernstein
AllianceBernstein
Tennessee
+$19.4M
4
LP
LMR Partners
United Kingdom
+$18.5M
5
SGCM
Sand Grove Capital Management
United Kingdom
+$17.5M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$32.3M
2
PWAM
Park West Asset Management
California
-$29.6M
3
WP
Woodline Partners
California
-$19.5M
4
MAM
Melqart Asset Management
United Kingdom
-$18.9M
5
Boston Partners
Boston Partners
Massachusetts
-$18.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$30.9M +$836K +9,009 +3%
HCM
27
Highbridge Capital Management
New York
$29.7M +$7.72M +83,200 +35%
Amundi
28
Amundi
France
$26.9M +$4.47M +48,196 +21%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$24.8M +$43.3K +467 +0.2%
Marshall Wace
30
Marshall Wace
United Kingdom
$24.6M -$2.17M -23,381 -8%
MP
31
Mangrove Partners
Connecticut
$24.3M – – –
VLKIM
32
Van Lanschot Kempen Investment Management
Netherlands
$24.1M -$8.83M -95,109 -27%
Northern Trust
33
Northern Trust
Illinois
$22.1M +$2.86M +30,803 +15%
WP
34
Woodline Partners
California
$22M -$19.5M -210,000 -47%
IG
35
ING Group
Netherlands
$20.4M +$4.22M +45,500 +26%
GF
36
Gabelli Funds
New York
$19.9M -$656K -7,065 -3%
PWAM
37
Park West Asset Management
California
$19.6M -$29.6M -319,257 -60%
GCIA
38
Gabelli & Co Investment Advisers
New York
$18.8M +$701K +7,550 +4%
Bank of Nova Scotia
39
Bank of Nova Scotia
Ontario, Canada
$17M – – –
Citigroup
40
Citigroup
New York
$16.5M -$767K -8,270 -4%
Morgan Stanley
41
Morgan Stanley
New York
$15.7M -$7.06M -76,075 -31%
WAM
42
Weiss Asset Management
Massachusetts
$14M +$14.1M +152,099 New
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$12.5M +$1.31M +14,116 +12%
Invesco
44
Invesco
Georgia
$12.1M -$4.19M -45,194 -26%
GLA
45
Great Lakes Advisors
Illinois
$11.9M -$730K -7,863 -6%
Renaissance Technologies
46
Renaissance Technologies
New York
$11.8M -$3.77M -40,600 -24%
State of Wisconsin Investment Board
47
State of Wisconsin Investment Board
Wisconsin
$11.7M -$1.37M -14,780 -10%
GAM
48
Gotham Asset Management
New York
$11.5M +$3.91M +42,098 +51%
M
49
Murchinson
Ontario, Canada
$11.4M +$4.71M +50,716 +69%
Citadel Advisors
50
Citadel Advisors
Florida
$11.2M +$11.3M +121,581 New
1
2
3 4 5

AMED Hedge Fund Activity: Q2 2024 in Review

288 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q2 2024, worth a combined $2.85B — down 0.2% from $2.86B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new AMED positions and 32 closed out — a net gain of 10 holders — while 93 added to existing stakes and 104 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $96.9M. The largest seller was Millennium Management, cutting an estimated $32.3M.

  • 288 institutional investors held Amedisys (AMED) as of Q2 2024, up from 283 in Q1 2024.
  • Funds reported $2.85B of Amedisys stock for Q2 2024, down 0.2% quarter-over-quarter.
  • 42 funds opened new Amedisys positions in Q2 2024 and 32 closed out, a net change of +10 holders.
  • The largest Amedisys buyer in Q2 2024 was Goldman Sachs, an estimated $96.9M added.
  • The largest Amedisys seller in Q2 2024 was Millennium Management, an estimated $32.3M sold.

Based on aggregated 13F filings for Q2 2024.